Due to external capacity constraints, we are pausing this appraisal of Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia following the receipt of company and stakeholder submissions which were received by deadline of 21 June 2022.
We anticipate that the appraisal will restart in mid- September 2022 when the allocated External Assessment Group will begin working on the External Assessment Report.
We are sorry for any inconvenience this change may cause and will continue to assess the work programme to see if the appraisal can be expedited in anyway as it progresses through the relevant stages.